Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance

MARAVAI LIFESCIENCES HOLDINGS, INC.

2024-Q2 EPS reported -$0.15 revenue$137,579,000

Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.
Net loss $(14.5)M vs $(11.9)M prior year; Adjusted EBITDA $16.9M up from $9.1M.
H1 2024 revenue $137.6M (-7% YoY); net loss $(37.2)M vs $(13.3)M.
Reaffirms FY2024 revenue guidance $265M-$285M.
Business updates: TriLink-Johns Hopkins collaboration, Flanders facilities milestones, new product launches.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.